Caricamento...
What is CD4+CD56+ malignancy and how should it be treated?
CD4+CD56+ malignancy is a rare neoplasm with a typical clinical pattern, an aggressive course and high early relapse rate despite good initial response to chemotherapy. In this review, the impact of different therapeutic approaches on clinical outcome has been studied. We evaluated 91 published case...
Salvato in:
| Pubblicato in: | Bone Marrow Transplant |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2003
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7091947/ https://ncbi.nlm.nih.gov/pubmed/13130309 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bmt.1704215 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|